Pharmaceutical composition for treating or preventing bacterial and mycoplasma diseases of livestock and use thereof

A composition and bacteriological technology, applied in the direction of antibacterial drugs, medical preparations with non-active ingredients, medical preparations containing active ingredients, etc., can solve the problems of laborious and laborious, reducing drug effects, multiple injections, etc., to achieve The effect of maintaining blood concentration, prolonging half-life, and slow release

Active Publication Date: 2013-07-24
LUOYANG HUIZHONG ANIMAL MEDICINE
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] According to the Guidelines for the Use of Veterinary Drugs of the People's Republic of China (Chemical Drug Volume), enrofloxacin injection needs 1-2 times to prevent and treat porcine respiratory diseases, and 2-3 times are required, which is laborious and laborious, and cannot improve the problem of stunted growth and development of pigs; Chinese patent CN101361709A discloses a long-acting enrofloxacin injection, which realizes long-acting and drug sustained release by adding PVP (polyvinylpyrrolidone). However, enrofloxacin is a concentration-dependent antibiotic, and adding a sustained-release agent will reduce drug effects
CN101933927A discloses the injection using enrofloxacin hydrate, yet the dosage form of this compound still needs multiple injections

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating or preventing bacterial and mycoplasma diseases of livestock and use thereof
  • Pharmaceutical composition for treating or preventing bacterial and mycoplasma diseases of livestock and use thereof
  • Pharmaceutical composition for treating or preventing bacterial and mycoplasma diseases of livestock and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Embodiment 1, preparation containing 10% W / V enrofloxacin hexahydrate injection

[0036] 1) Preparation of 10% W / V enrofloxacin hexahydrate composition

[0037] Enrofloxacin hexahydrate (prepared according to the method of CN101933927A Example 1 is 74.0% (the raw material content is calculated as enrofloxacin, the same below)): 10% W / V (calculated as enrofloxacin)

[0038] Cosolvent: KOH (Tianjin Comio) 1.5% W / V; Arginine (Hubei Yuancheng Pharmaceutical Co., Ltd.) 10% W / V

[0039] Preservative: n-Butanol 3% W / V

[0040] Carrier: water for injection to a full dose of 1000ml

[0041] Preparation steps:

[0042] 1) Preparation of KOH solution: Weigh 15g of KOH, add 50ml of water for injection, stir to dissolve and dilute to 100ml;

[0043] 2) Mix 600ml of water for injection and 30g of n-butanol evenly, and control the temperature at 20°C-30°C during mixing;

[0044] 3) Add 135.1 g of enrofloxacin hexahydrate and stir to mix evenly;

[0045] 4) Slowly add the above K...

Embodiment 2

[0047] Embodiment 2, preparation of compound 10% W / V enrofloxacin hexahydrate injection

[0048] Enrofloxacin hexahydrate is prepared according to (according to CN101933927A embodiment 1, content is 74.0% based on enrofloxacin): 10% W / V

[0049] Butafosfos (Hangzhou Foster Pharmaceutical Co., Ltd. content 99.8%) 2.5W / V

[0050] Cosolvent: KOH 1.5% W / V Arginine 10% W / V

[0051] Preservative: n-Butanol 3% W / V

[0052] Carrier: water for injection to the full amount of 1000ml

[0053] Preparation steps:

[0054] 1) Preparation of KOH solution: Weigh 15g of KOH, add 100ml of water for injection, stir to dissolve and set the volume to 200ml;

[0055] 2) Mix 600ml of water for injection and 30g of n-butanol evenly, and control the temperature at 20°C-30°C during mixing;

[0056] 3) Add 135.1 g of enrofloxacin hexahydrate and stir to mix evenly;

[0057]4) Slowly add the above-mentioned KOH solution, then add 100g of arginine and 25g of butafosf in turn and stir; stir to dissol...

Embodiment 3

[0059] Embodiment 3, preparation of compound 15% W / V enrofloxacin hexahydrate injection

[0060] Enrofloxacin hexahydrate (prepared according to N101933927A Example 1 content is 74.0% based on enrofloxacin): 15% W / V

[0061] Butafosfos (Hangzhou First Pharmaceutical Co., Ltd. content 99.8%) 4.0% W / V

[0062] Co-solvent: KOH 3.0%W / V

[0063] Preservative: n-Butanol 3% W / V

[0064] Carrier: water for injection to the full amount of 1000ml

[0065] Preparation steps:

[0066] 1) Preparation of KOH solution: Weigh 30g of KOH, add 100ml of water for injection, stir to dissolve and set the volume to 200ml;

[0067] 2) Mix 600ml of water for injection and 30g of n-butanol evenly, and control the temperature at 20°C-30°C during mixing;

[0068] 3) Add 202.3 g of enrofloxacin hexahydrate and stir to mix evenly;

[0069] 4) Slowly add the above KOH solution, and stir butafosfos 40g to dissolve it;

[0070] 5) Dilute the volume of water for injection to 1000ml, mix well, and filte...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition for treating or preventing bacterial and mycoplasma diseases of livestock and a use thereof. The pharmaceutical composition comprises 5 to 15% w / v of enrofloxacin, an enrofloxacin hydrate or an enrofloxacin derivative (such as enrofloxacin base) and 1 to 10% w / v of butafosfan. The pharmaceutical composition containing enrofloxacin can reduce injection frequency, can treat or prevent bacterial and mycoplasma diseases of livestock, and can improve piglet weight gain after being injected into the piglet.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating or preventing livestock bacterial and mycoplasma diseases and its application, in particular to a pharmaceutical composition containing enrofloxacin hydrate and its application. Background technique [0002] Pig respiratory diseases have become the main problem in pig production. Almost all large-scale pig farms have respiratory diseases. The incidence is usually 30% to 60%, and the mortality rate is 5% to 30%. At the same time, it is difficult to prevent and control. The economic losses caused are huge. Respiratory disease problems exist in all stages from sows, suckling pigs, nursery pigs to finishing pigs. In actual production, the respiratory diseases that occur are basically caused by cross-infection of various pathogens, so it is called porcine respiratory disease syndrome. Clinically, the main symptoms are fever, cyanosis, dyspnea, cough, decreased appetite, and stunted growth ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/496A61K47/24A61P31/04
Inventor 张许科刘兴金李兴国
Owner LUOYANG HUIZHONG ANIMAL MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap